Neisseria Meningitidis Completed Phase 3 Trials for Streptococcus pneumoniae type 19f capsular polysaccharide antigen (DB10336)

DBCOND0030896 (Neisseria Meningitidis)Completed3 IdentifierTitlePurposeDrugs
NCT01553279Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)Prevention
NCT01978093Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of AgePrevention